Innate Pharma S.A. ADR (IPHA)

Jan 10, 2025, 1:00 AM EST - 11 days ago

Innate Pharma Announces Transformative Strategy to Accelerate Growth

Dec 20, 2024, 1:00 AM EST - 4 weeks ago

Innate Pharma to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Dec 9, 2024, 1:00 AM EST - 6 weeks ago

Innate Pharma Presents Lacutamab Improved Health-related Quality of Life Data at ASH 2024 From TELLOMAK Phase 2 Study in Patients With Cutaneous T Cell Lymphoma

Dec 6, 2024, 1:00 AM EST - 6 weeks ago

Innate Pharma and the Institute for Follicular Lymphoma Innovation (IFLI) Announce up to $7.9M Investment From IFLI to Support IPH6501 Development in Follicular Lymphoma

Dec 3, 2024, 1:00 AM EST - 7 weeks ago

Innate Pharma Highlights Abstracts Selected for the ASH Annual Meeting 2024

Nov 25, 2024, 11:54 AM EST - 2 months ago

Innate Pharma: Looking Like A Company We'll Regret Ignoring

Nov 20, 2024, 1:00 AM EST - 2 months ago

Innate Pharma Releases Its 2025 Financial Calendar

Nov 19, 2024, 1:00 AM EST - 2 months ago

Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501

Nov 13, 2024, 1:09 PM EST - 2 months ago

Innate Pharma S.A. (IPHA) Q3 2024 Earnings Call Transcript

Nov 13, 2024, 1:00 AM EST - 2 months ago

Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results

Nov 8, 2024, 1:00 AM EST - 2 months ago

Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024

Nov 7, 2024, 1:00 AM EST - 2 months ago

Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates

Oct 29, 2024, 2:00 AM EDT - 3 months ago

Innate Pharma Announces Its Participation in Upcoming Investor Conferences

Oct 14, 2024, 1:00 AM EDT - 3 months ago

Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board

Sep 30, 2024, 1:00 AM EDT - 4 months ago

Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024

Sep 23, 2024, 1:00 AM EDT - 4 months ago

Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors

Sep 12, 2024, 11:19 AM EDT - 4 months ago

Innate Pharma S.A. (IPHA) Q2 2024 Earnings Call Transcript

Sep 12, 2024, 1:00 AM EDT - 4 months ago

Innate Pharma Reports First Half 2024 Business Update and Financial Results

Sep 9, 2024, 1:00 AM EDT - 4 months ago

Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024

AZN

Sep 5, 2024, 1:00 AM EDT - 4 months ago

Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update

Sep 4, 2024, 1:00 AM EDT - 4 months ago

Innate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference

Aug 1, 2024, 1:00 AM EDT - 6 months ago

Innate Pharma Announces Its Participation in Upcoming Investor Conference

Jun 17, 2024, 1:00 AM EDT - 7 months ago

Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial

Jun 4, 2024, 1:00 AM EDT - 8 months ago

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides

May 24, 2024, 1:00 AM EDT - 8 months ago

Innate Pharma Highlights Abstracts Selected for ASCO 2024 Annual Meeting

May 23, 2024, 4:00 PM EDT - 8 months ago

Outcome of Innate Pharma's 2024 Annual General Meeting

May 21, 2024, 1:00 AM EDT - 8 months ago

Innate Pharma: Clarification Regarding SAR443579 Designation

May 15, 2024, 1:00 AM EDT - 8 months ago

Innate Pharma Highlights Abstracts Selected for EHA 2024 Congress

May 14, 2024, 11:03 AM EDT - 8 months ago

Innate Pharma S.A. (IPHA) Q1 2024 Earnings Call Transcript

May 14, 2024, 1:00 AM EDT - 9 months ago

Innate Pharma Reports First Quarter 2024 Business Update and Financial Results

May 7, 2024, 1:00 AM EDT - 9 months ago

Innate Pharma Announces Conference Call and Webcast for Q1 2024 Business Update

Apr 15, 2024, 1:00 AM EDT - 10 months ago

Innate Pharma to Hold Its Annual General Meeting of Shareholders on May 23, 2024

Apr 15, 2024, 1:00 AM EDT - 10 months ago

Innate Pharma Announces Advancement of Sanofi-developed NK Cell Engager SAR443579 / IPH6101 Progressing to Phase 2 for Blood Cancer Patients

Apr 10, 2024, 1:00 AM EDT - 10 months ago

Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

Apr 5, 2024, 3:34 AM EDT - 10 months ago

Innate Pharma Files Its 2023 Universal Registration Document (Document d'enregistrement Universel) and 2023 Annual Report on Form 20-F

Mar 21, 2024, 12:42 PM EDT - 10 months ago

Innate Pharma S.A. (IPHA) Q4 2023 Earnings Call Transcript

Mar 21, 2024, 2:00 AM EDT - 10 months ago

Innate Pharma Reports Full Year 2023 Financial Results and Business Update

Mar 19, 2024, 2:00 AM EDT - 11 months ago

Innate Pharma Announces Its Participation to Upcoming Investor Conference

Mar 14, 2024, 2:00 AM EDT - 11 months ago

Innate Pharma Announces Conference Call and Webcast for Full Year 2023 Financial Results

Mar 6, 2024, 1:00 AM EST - 11 months ago

Innate Pharma to Present Nectin-4 Antibody Drug Conjugate IPH45 Preclinical Data at AACR 2024

Mar 6, 2024, 1:00 AM EST - 11 months ago

Innate Pharma: First Patient dosed in Phase 1/2 study of IPH6501 in relapsed /refractory B-Cell non-Hodgkin's Lymphoma

Jan 11, 2024, 8:42 AM EST - 1 year ago

Innate Pharma: Worth A Deeper Look

Jan 4, 2024, 1:00 AM EST - 1 year ago

Innate Pharma Announces U.S. FDA Lifts Partial Clinical Hold on Lacutamab Clinical Program

Jan 4, 2024, 12:59 AM EST - 1 year ago

Innate Pharma Strengthens Leadership and Appoints Two New Members to Its Executive Board

Dec 19, 2023, 1:00 AM EST - 1 year ago

Innate Pharma Announces Licensing of a Fourth Natural Killer Cell Engager in Oncology to Sanofi

SNY

Dec 18, 2023, 1:00 AM EST - 1 year ago

Innate Pharma Announces Leadership Change

Dec 11, 2023, 1:00 AM EST - 1 year ago

Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023

Dec 10, 2023, 1:00 AM EST - 1 year ago

Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Patients With Sézary Syndrome at ASH 2023

Nov 27, 2023, 1:00 AM EST - 1 year ago

Innate Pharma to Host Virtual KOL Event on Lacutamab

Nov 14, 2023, 5:56 PM EST - 1 year ago

Innate Pharma S.A. (IPHA) Q3 2023 Earnings Call Transcript